NEWS

EB was brought to the heart of European decision-making during a dedicated event at the European Parliament for Rare Disease Day 2026.

DEBRA Spain held its first ever EB Nurses Conference, bringing together more than 80 healthcare professionals from across Spain.

DEBRA UK has recently launched a new EB CPD module authored by Dr Anna Martinez from the EB healthcare centre of excellence at Great Ormond Street Hospital in London with the objective to help raise awareness of EB with healthcare professionals (HCPs), particularly general practitioners (GPs).

Explore the latest approved and emerging EB treatments, along with new wound-care innovations, in this expert-led DEBRA International webinar—now available to watch on demand.

UZ Leuven and NIHDI have signed a key convention, enabling tailored care plans and coordinated support for EB patients, a major step forward in rare disease care.

This is an essential tool for health professionals, highlighting management priorities in the care of oesophageal strictures in inherited epidermolysis bullosa (EB) and provide clinicians access to recommended diagnostic, treatment, and preventative care options.

The FDA has approved ZEVASKYN™ (prademagene zamikeracel), the third therapy available for individuals with epidermolysis bullosa (EB)

An Educational Day was organised for patients with EB and some Healthcare Specialists to highlight the importance of oral health in Jordan.

A new clinical trial is looking for 74 patients with severe forms of EB in renowned study centers across the world.

DEBRA International held two sessions and a booth at the 2024 EWMA in London.

BUR-EB's new study aims to assess patients’ quality of life and the financial burden of EB on their families.

During the visit, Belgian Minister made an important announcement for better care for patients suffering with four types of rare diseases.

DEBRA Croatia marks Rare Disease Day with three new workshops for policy makers and students.

It highlights management priorities in neonatal EB care and provide clinicians access to recommended treatment and preventative care options

The online survey takes 10-20 minutes to complete and is open only until December 31, 2023.

FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and...

The DEBRA France Association organized its 4th annual meeting of epidermolysis bullosa professionals at the Necker Hospital in Paris.

Contracts for two new research projects have been successfully issued by EB Resnet 2022.

DEBRA Indonesia hosted a free webinar to increase awareness and knowledge of oral and dental health for EB patients

DEBRA Spain are delighted to announce they will be dedicating €100,000 to a research project to develop a topical gel to treat RDEB wounds.